4. Subjects with known EGFR mutations or ALK or ROS1 gene rearrangements have failed (progressive disease or unacceptable toxicity) at least one prior EGFR or ALK or ROS1 tyrosine kinase inhibitor (TKI), respectively. There is no limit on lines of prior anti-cancer therapy.